1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,430 | 5,770 | 11:26 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.09. | XSpray Pharma AB: Xspray's rights issue oversubscribed - over-allotment issue increased and fully utilized | 165 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA... ► Artikel lesen | |
| 26.08. | Listing of subscription rights and paid subscription shares of XSpray Pharma AB | 266 | GlobeNewswire | With effect from August 27, 2025, the subscription rights of XSpray Pharma AB will be traded on the list for Equity rights. Trading will continue up until and including September 04, 2025.
Instrument:
Subscription... ► Artikel lesen | |
| 25.08. | XSpray Pharma AB: Xspray publishes disclosure document regarding rights issue | 244 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA... ► Artikel lesen | |
| 21.08. | XFRA CAPITAL ADJUSTMENT INFORMATION - 21.08.2025 | 273 | Xetra Newsboard | Das Instrument 6O1 CA13810W1023 CANTER RESOURCES CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 21.08.2025 und ex Kapitalmassnahme am 22.08.2025 The instrument 6O1 CA13810W1023 CANTER RESOURCES... ► Artikel lesen | |
| 19.08. | XSpray Pharma AB: Xspray Pharma Submits XS003 to the FDA - The Company's Second Product Candidate from the HyNap Platform | 360 | GlobeNewswire (Europe) | Xspray Pharma (Nasdaq Stockholm: XSPRAY) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate XS003 (nilotinib) for the treatment of chronic... ► Artikel lesen | |
| XSPRAY PHARMA Aktie jetzt für 0€ handeln | |||||
| 15.08. | XSpray Pharma AB: Interim Report Second Quarter 2025 | 134 | GlobeNewswire (Europe) | April-June 2025, GroupNet sales amounted to SEK 0 thousand (0)Earnings before tax amounted to SEK -44,885 thousand (-53,620)Earnings per share before dilution amounted to SEK -2.35 (-1.64)Cash flow... ► Artikel lesen | |
| 12.08. | Xspray Pharma Signs License Agreement With Handa Therapeutics For Dasatinib Product | 1 | RTTNews | ||
| 12.08. | XSpray Pharma AB: Xspray Pharma signs license agreement with Handa Therapeutics - to receive up to double-digit royalty on Handa's net proceeds | 175 | GlobeNewswire (Europe) | Xspray Pharma ("Xspray") has entered into a license agreement with Handa Therapeutics ("Handa") granting Handa a non-exclusive license to certain Xspray patents. The license covers commercialization... ► Artikel lesen | |
| 11.07. | XSpray Pharma AB: XSpray Pharma achieves significant milestone - demonstrating bioequivalence with absorption advantages compared to Tasigna | 148 | GlobeNewswire (Europe) | Xspray Pharma has now completed the population pharmacokinetic (PopPK) modeling that constitutes key regulatory documentation ahead of submitting a New Drug Application (NDA) for the product candidate... ► Artikel lesen | |
| 27.06. | XSpray Pharma AB: Xspray Pharma Passes FDA Pre-Approval Inspection - Key Regulatory Milestone Achieved for Dasynoc | 415 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) today announces that the U.S. Food and Drug Administration (FDA) has conducted a successful Pre-Approval Inspection (PAI) of the company's manufacturing lines, located at a contract... ► Artikel lesen | |
| 14.05. | XSpray Pharma AB: FDA sets PDUFA-date for Xspray Pharma's re-submitted application for Dasynoc | 271 | GlobeNewswire (Europe) | The U.S. Food and Drug Administration (FDA) has acknowledged receipt of Xspray Pharma's re-submitted NDA (New Drug Application) for Dasynoc®. The re-submission is based on a CRL (Complete Response Letter)... ► Artikel lesen | |
| 13.05. | XSpray Pharma AB: Bulletin from the annual general meeting of Xspray Pharma AB (publ) | 112 | GlobeNewswire (Europe) | The following resolutions were passed at the annual general meeting (the "AGM") of Xspray Pharma AB (publ) ("Xspray") on 13 May 2025.
Adoption of income statement and balance sheet for the financial... ► Artikel lesen | |
| 07.05. | XSpray Pharma AB: Interim Report First Quarter 2025 | 164 | GlobeNewswire (Europe) | January - March 2025, Group• Net sales amounted to SEK 0 thousand (0)• Earnings before tax amounted to SEK -42,321 thousand (-67,781)• Earnings per share before dilution amounted to SEK -1.14 (-2.17)•... ► Artikel lesen | |
| 08.04. | XSpray Pharma AB: Xspray Pharma re-submits its FDA application | 245 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) has re-submitted its application for market approval for Dasynoc®, the company's lead product candidate, an amorphous dasatinib for the treatment of leukemia. The application... ► Artikel lesen | |
| 12.02. | XSpray Pharma AB: Interim Report Fourth Quarter 2024 | 122 | GlobeNewswire (Europe) | October-December 2024, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -82,002 thousand (-54,513)Earnings per share before dilution amounted to SEK -2.36 (-1.85)Cash flow... ► Artikel lesen | |
| 20.01. | XSpray Pharma AB: Xspray Pharma reports strong interim data for product candidate XS003 - confirms plan to apply for market approval in H1 2025 | 151 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) today presents interim data from a food interaction study with the nilotinib product candidate (XS003). The results confirm the benefits of the company's patented HyNap technology... ► Artikel lesen | |
| 14.11.24 | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Xspray Pharma AB | 379 | GlobeNewswire | With effect from November 15, 2024, the subscription rights of Xspray Pharma
AB will be traded on the list for Equity rights. Trading will continue up until
and including November 26, 2024.
Instrument:... ► Artikel lesen | |
| 12.11.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.11.2024 | 2.702 | Xetra Newsboard | Das Instrument 3O41 BMG611881019 LIBERTY GLOBAL LTD CL.A EQUITY wird cum Kapitalmassnahme gehandelt am 12.11.2024 und ex Kapitalmassnahme am 13.11.2024 The instrument 3O41 BMG611881019 LIBERTY GLOBAL... ► Artikel lesen | |
| 06.11.24 | XSpray Pharma AB: Interim Report Third Quarter 2024 | 194 | GlobeNewswire (Europe) | July - September 2024, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -82,272 thousand (-38,942)Earnings per share before dilution amounted to SEK -2.44 (-1.59)Cash flow... ► Artikel lesen | |
| 06.11.24 | XSpray Pharma AB: Xspray resolves on a rights issue of approximately SEK 135 million and raises a loan of SEK 100 million | 240 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TOURMALINE BIO | 47,860 | 0,00 % | Novartis Pharma AG: Novartis announces commencement of tender offer to acquire Tourmaline Bio | Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis ("Purchaser"), has commenced a tender offer... ► Artikel lesen | |
| EVOTEC | 6,502 | +2,62 % | Evotec: Aktie in Problemen? - Aixtron, Circus, Commerzbank, Gerresheimer und Rheinmetall im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| QIAGEN | 39,350 | +0,41 % | ROUNDUP/Aktien Frankfurt Eröffnung: Moderate Verluste - Richtungssuche | FRANKFURT (dpa-AFX) - Nach den leichten Gewinnen vom Vortag haben die Anleger am deutschen Aktienmarkt am Donnerstag wieder etwas auf die Bremse getreten. "Die Richtungssuche geht weiter", konstatierte... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 10,085 | 0,00 % | ARS Pharma secures $250M loan to accelerate Neffy rollout | ||
| BICARA THERAPEUTICS | 16,610 | 0,00 % | Bicara Therapeutics: TD Cowen bekräftigt Kaufempfehlung nach Merus-Übernahme | ||
| PHATHOM PHARMACEUTICALS | 12,290 | 0,00 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 19,750 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025 | ||
| VERA THERAPEUTICS | 28,790 | 0,00 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
| DISC MEDICINE | 67,11 | 0,00 % | Disc Medicine Inc: Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP) | Disc is seeking accelerated approval and priority review of its NDA submissionFDA decision to accept and file the NDA for review occurs within 60 days of submission WATERTOWN, Mass., Sept. 30,... ► Artikel lesen | |
| BIONTECH | 87,60 | +0,63 % | BioNTech fürchtet neue Zölle, Eli Lilly tritt auf die Bremse, Daimler Truck verliert trotz Rüstungsfantasien und auch Siemens Healthineers zittert | Erst vor wenigen Tagen kam die für viele erleichternde Nachricht, dass eine Zollvereinbarung zwischen den USA und der EU rückwirkend zum 1. August greift, was vor allem Autobauern ein wenig Luft zum... ► Artikel lesen | |
| SIONNA THERAPEUTICS | 28,470 | 0,00 % | Sionna Therapeutics, Inc.: Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis | WALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm... ► Artikel lesen | |
| ZENAS BIOPHARMA | 22,120 | 0,00 % | Zenas BioPharma Secures Up To $300 Mln Funding From Royalty Pharma For Obexelimab | WASHINGTON (dpa-AFX) - Royalty Pharma plc (RPRX) and Zenas BioPharma, Inc. (ZBIO) Tuesday announced that Royalty Pharma will provide up to $300 million in exchange for a royalty on sales of... ► Artikel lesen | |
| ARCELLX | 82,05 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 52,95 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| VALNEVA | 5,090 | -0,59 % | Valneva: Chikungunya-Impfstoff zeigt über vier Jahre stabile Wirksamkeit | Valneva hat neue Daten zur Antikörperpersistenz seines Chikungunya-Impfstoffs IXCHIQ veröffentlicht. Vier Jahre nach einer einmaligen Impfung zeigten nach Angaben des Biotech-Unternehmens vom Dienstag... ► Artikel lesen |
XSPRAY PHARMA AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,100 (+1,90 %) liegt der Kurs bei 5,370 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XSPRAY PHARMA AB finden Sie auf Wallstreet Online.